This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is AMNEAL PHARMACEUTICALS, INC. (AMRX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (AMRX) Outperforming Other Medical Stocks This Year?
RedHill's (RDHL) RHB-204 Gets FDA Orphan Drug Designation
by Zacks Equity Research
RedHill (RDHL) gets Orphan Drug status from the FDA for the treatment of nontuberculous mycobacteria (NTM) disease.
Amneal Pharmaceuticals (AMRX) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Amneal (AMRX) delivered earnings and revenue surprises of 30.00% and 3.73%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Amneal (AMRX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Amneal (AMRX) will provide financial updates when it reports second-quarter 2020 results.
Amneal Pharmaceuticals (AMRX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Amneal Pharmaceuticals (AMRX) closed the most recent trading day at $4.33, moving -0.69% from the previous trading session.
Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amneal Pharmaceuticals (AMRX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Amneal Pharmaceuticals (AMRX) closed at $4.46, marking a +0.45% move from the previous day.
Can Amneal (AMRX) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Amneal Pharmaceuticals (AMRX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Amneal Pharmaceuticals (AMRX) closed the most recent trading day at $4.86, moving +0.21% from the previous trading session.
Company News for Jul 13, 2020
by Zacks Equity Research
Companies in the news are: BNGO, AMRX, ALT, EXPR
Amneal Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Amneal Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.
Amneal Pharmaceuticals (AMRX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Amneal Pharmaceuticals (AMRX) closed the most recent trading day at $4.51, moving -0.66% from the previous trading session.
Pacira (PCRX) Provides Preliminary Results for Second Quarter
by Zacks Equity Research
Pacira (PCRX) reports preliminary results for the second quarter of 2020. The company's product sales are hurt by the COVID-19 pandemic. The stock fell in pre-market trading.
AMRX vs. COLL: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AMRX vs. COLL: Which Stock Is the Better Value Option?
Profound Medical (PROF) Looks Good: Stock Adds 5.4% in Session
by Zacks Equity Research
Profound Medical (PROF) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
CytoDyn Signs MOU With NIH of Mexico for Coronavirus Study
by Zacks Equity Research
CytoDyn's (CYDY) shares rise more than 20% as it inks an MOU with NIH of Mexico to conduct a COVID-19 study on leronlimab.
Xeris Pharmaceuticals (XERS) in Focus: Stock Moves 6.8% Higher
by Zacks Equity Research
Xeris Pharmaceuticals (XERS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Zogenix Gets FDA Nod for Dravet Syndrome Seizure Treatment
by Zacks Equity Research
Zogenix (ZGNX) gets FDA nod for Fintepla oral solution, CIV for the treatment of seizures associated with Dravet Syndrome in patients 2 years of age or older.
Onconova Initiates Phase I/IIa Study on Lung Cancer Candidate
by Zacks Equity Research
Onconova (ONTX) starts investigator-initiated phase I/IIa study of oral rigosertib plus Bristol-Myers Squibb's Opdivo in advanced metastatic KRAS-mutated lung adenocarcinoma.
AMRX vs. COLL: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AMRX vs. COLL: Which Stock Is the Better Value Option?
Jazz Pharmaceuticals (JAZZ) in Focus: Stock Moves 5.6% Higher
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Moving Average Crossover Alert: Amneal Pharmaceuticals
by Zacks Equity Research
Amneal Pharmaceuticals, Inc. (AMRX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Actinium Pharmaceuticals (ATNM) Jumps: Stock Rises 6.7%
by Zacks Equity Research
Actinium Pharmaceuticals (ATNM) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Amneal's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Amneal Pharmaceuticals.
AMRX or COLL: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMRX vs. COLL: Which Stock Is the Better Value Option?